Details of the Active Pharmaceutical Ingredient (API)
General Information of API (ID: D00118) | |||||
---|---|---|---|---|---|
Name |
Chenodeoxycholic acid
|
||||
Synonyms |
Click to Show/Hide the Synonyms of This API
chenodeoxycholic acid; Chenodiol; Chenix; Chenic acid; Chenodeoxycholate; 474-25-9; Chenodesoxycholic acid; Gallodesoxycholic acid; Chendol; Anthropodeoxycholic acid; Anthropodesoxycholic acid; Chenofalk; Anthropododesoxycholic acid; Chenodesoxycholsaeure; Xenbilox; Chenocholic acid; Chenodiol [USAN]; 3alpha,7alpha-Dihydroxy-5beta-cholan-24-oic acid; Sodium chenodeoxycholate; Acido chenodeoxicholico; 3alpha,7alpha-Dihydroxy-5beta-cholanic acid; Chenodesoxycholsaeure [German]; Acide chenodeoxycholique; 7-alpha-Hydroxylithocholic acid; Acidum chenodeoxycholicum; UNII-0GEI24LG0J; 7alpha-hydroxylithocholic acid; Acide chenodeoxycholique [INN-French]; Acido chenodeoxicholico [INN-Spanish]; Acidum chenodeoxycholicum [INN-Latin]; 3-alpha,7-alpha-Dihydroxycholanic acid; 3-alpha,7-alpha-Dihydroxycholansaeure [German]; 3-alpha,7-alpha-Dihydroxycholansaeure; 0GEI24LG0J; 3-alpha,7-alpha-Dihydroxy-5-beta-cholan-24-oic acid; CHEBI:16755; Cholan-24-oic acid, 3,7-dihydroxy-, (3alpha,5beta,7alpha)-; Chenodiol (USAN); Cholan-24-oic acid, 3,7-dihydroxy-, (3a,5b,7a)-; 5-beta-Cholan-24-oic acid, 3-alpha,7-alpha-dihydroxy-; (3alpha,5beta,7alpha,8xi)-3,7-dihydroxycholan-24-oic acid; Henohol; Chenique Acid; DSSTox_CID_260; DSSTox_RID_75469; DSSTox_GSID_20260; Cholan-24-oic acid, 3,7-dihydroxy-, (3-alpha,5-beta,7-alpha)- (9CI); 5beta-Cholanic acid-3alpha,7alpha-diol; Chendeoxycholic Acid; CCRIS 2195; EINECS 207-481-8; NSC 657949; Chenocedon; Chendal; Chenocol; Chenodex; Chenorm; Chenossil; Cholanorm; Fluibil; Hekbilin; Kebilis; Cholan-24-oic acid, 3,7-dihydroxy-, (3.alpha.,5.beta.,7.alpha.)-; MFCD00064142; NSC657949; NSC-657949; NCGC00016387-02; CAS-474-25-9; (+)-chenodeoxycholate; Prestwick0_000285; Prestwick1_000285; Prestwick2_000285; Prestwick3_000285; Spectrum5_002009; CHENIX (TN); (+)-chenodeoxycholic acid; bmse000908; (3alpha,5beta,7alpha)-3,7-dihydroxycholan-24-oic acid; 7a-Hydroxy-desoxycholsaeure; EC 207-481-8; BIDD:PXR0056; Chenodeoxycholic acid [INN]; SCHEMBL25055; BSPBio_000190; GTPL608; MLS002154253; 3a,7a-dihydroxy-5b-cholanate; SPBio_002409; BPBio1_000210; CHEMBL240597; Chenodeoxycholic acid, >=97%; DTXSID2020260; 7.alpha.-Hydroxylithocholic acid; BDBM21674; 3a,7a-dihydroxy-5b-cholanic acid; HMS1568J12; HMS2095J12; HMS2234I22; HMS3712J12; Chenodeoxycholic acid (JP16/INN); Chenodeoxycholic acid (JP17/INN); ZINC3914808; Tox21_110412; Tox21_200491; (3beta,7beta,8xi,9xi,14xi,17alpha)-3,7-dihydroxycholan-24-oic acid; 3a,7a-dihydroxy-5b-cholan-24-oate; Cholan-24-oic acid, 3,7-dihydroxy-, (3-alpha,5-beta,7-alpha)-; HSCI1_000210; LMST04010032; SBB002935; AKOS024280614; CCG-220285; CS-0834; DB06777; MCULE-3421183878; SMP1_000064; 3.alpha.,7.alpha.-Dihydroxycholansaeure; 3a,7a-dihydroxy-5b,14a,17b-cholanate; 3a,7a-dihydroxy-5b-cholan-24-oic acid; NCGC00142400-03; NCGC00142400-04; NCGC00142400-08; NCGC00258045-01; 3.alpha.,7.alpha.-Dihydroxycholanic acid; AS-13636; HY-76847; SMR000857194; ST033520; 3a,7a-dihydroxy-5b,14a,17b-cholanic acid; AB00513822; (3a,5b,7a)-3,7-dihydroxy-cholan-24-oate; 3alpha, 7alpha-dihydroxy-5beta-cholanoic acid; 3alpha, 7alpha,-dihydroxy-5beta-cholanic acid; C-2900; C02528; D00163; J10019; W-5059; (3a,5b,7a)-3,7-dihydroxy-cholan-24-oic acid; 25795-EP2289883A1; 25795-EP2295411A1; 25795-EP2315303A1; AB00513822-06; AB00513822_07; Q419028; 3.alpha.,7.alpha.-Dihydroxy-5.beta.-cholanic acid; Dihydroxy-3.alpha.,7.alpha.(5.beta.)Cholanic acid; Leadiant (formerly Chenodeoxycholic acid sigma-tau); A)-3,7-Dihydroxycholan-24-oic Acid; 3.alpha.,7.alpha.-Dihydroxy-5.beta.-cholanoic acid; BRD-K18135438-001-16-7; 0DBBBC66-0CFA-4DB9-97F4-5B1492756A02; Z1270387252; 3.alpha.,7.alpha.-Dihydroxy-5.beta.-cholan-24-oic acid; UNII-JIY1ILR284 component RUDATBOHQWOJDD-BSWAIDMHSA-N; 5.beta.-Cholan-24-oic acid, 3.alpha.,7.alpha.-dihydroxy-; (3alpha,5alpha,7beta,8alpha,17alpha)-3,7-dihydroxycholan-24-oic acid; 3,7-Dihydroxycholan-24-oic acid, (3.alpha.,5.beta.,7.alpha.)- #; Chenodeoxycholic acid, 500 mug/mL in methanol, certified reference material; Chenodeoxycholic acid, European Pharmacopoeia (EP) Reference Standard; Cholan-24-oic acid, 3,7-dihydroxy-, (3-.alpha., 5-.beta., 7-.alpha.)-; 24404-86-2
|
||||
Clinical Status |
Approved
|
||||
Disease Indication | Cholelithiasis | ICD-11: DC11 | [1] | ||
PubChem CID | |||||
Formula |
C24H40O4
|
||||
Canonical SMILES |
C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)C
|
||||
InChI |
1S/C24H40O4/c1-14(4-7-21(27)28)17-5-6-18-22-19(9-11-24(17,18)3)23(2)10-8-16(25)12-15(23)13-20(22)26/h14-20,22,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15+,16-,17-,18+,19+,20-,22+,23+,24-/m1/s1
|
||||
InChIKey |
RUDATBOHQWOJDD-BSWAIDMHSA-N
|
||||
Click to Show/Hide the Molecular Data (Structure/Property) of This API | |||||
Structure |
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=10133"></iframe>
|
||||
3D MOL | 2D MOL | ||||
Physicochemical Properties | Molecular Weight | 392.6 | Topological Polar Surface Area | 77.8 | |
XlogP | 4.9 | Complexity | 605 | ||
Heavy Atom Count | 28 | Rotatable Bond Count | 4 | ||
Hydrogen Bond Donor Count | 3 | Hydrogen Bond Acceptor Count | 4 | ||
Full List of Drug Formulations (DFMs) Containing This API | ||||||
---|---|---|---|---|---|---|
Chenodeoxycholic acid 250 mg tablet | Click to Show/Hide the Full List of Formulation(s): 1 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Sodium lauryl sulfate; Magnesium stearate; Glycerin; Silicon dioxide; Cellulose, microcrystalline; Methylcellulose (100 mpa.s); Sodium starch glycolate type a potato
|
|||||
Dosage Form | Oral Tablet | |||||
Company | Retrophin | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Sodium lauryl sulfate | DIG Info | Solute carrier SLCO2B1 (Ki = 1.98 uM) | [2] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [3] | |||
Silicon dioxide | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [3] | |||
Chenodiol 250mg tablet | Click to Show/Hide the Full List of Formulation(s): 1 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Pregelatinized Starch; Silicon Dioxide; Microcrystalline Cellulose; Sodium Starch Glycollate; ; Magnesium Stearate; The Thin-Film Coating Contains: Opadry Ys-2-7035 [Consisting Of Methylcellulose, Glycerin]; Sodium Lauryl Sulfate
|
|||||
Dosage Form | Tablet | |||||
Company | Lgm Pharma Solutions | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Sodium lauryl sulfate | DIG Info | Solute carrier SLCO2B1 (Ki = 1.98 uM) | [2] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [3] | |||
Silicon dioxide | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [3] | |||
Pregelatinized starch | DIG Info | Multidrug resistance protein 1 (Protein expression downregulation) | [3] | |||
If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.